8/1016 sources · 7 publishersUpdated Nov 9, 05:40 UTC
Amneal Pharmaceuticals raises 2026 revenue and earnings guidance after Q3 2026 results
Amneal Pharmaceuticals reported Q3 2026 revenue of $863 million, up 10% year‑over‑year, and adjusted earnings per share of $0.26, a 53% increase. Adjusted EBITDA rose 30% to $207 million. The company lifted its full‑year 2026 revenue outlook to $3.15‑$3.25 billion and its adjusted EPS outlook to $1.04‑$1.08 per share.
Why it matters
The raised guidance expands the revenue target range for 2026, implying higher top‑line growth for investors (the company said it expects the higher range). The higher adjusted EPS outlook suggests improved profitability, which may support a higher valuation.
Key facts
- 1Q3 2026 revenue was $863 million, up 10% YoY. tradingview.com
- 2Adjusted EBITDA for Q3 2026 was $207 million, up 30% YoY. tradingview.com
- 3Adjusted EPS for Q3 2026 was $0.26 per share. seekingalpha.com
- 4Full‑year 2026 adjusted EPS guidance was raised to $1.04‑$1.08 per share. seekingalpha.com
- 5Full‑year 2026 net revenue guidance was raised to $3.15‑$3.25 billion. seekingalpha.com
Summary written by AlphAI AI Desk from 16 of 16 sources. Not investment advice. Figures are as stated by the linked sources.